Cargando…

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine kinase inhibitor sunitinib has clearly demonstrated a clinical benefit in terms of response rate and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulet-Margalef, Nuria, Garcia-del-Muro, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171199/ https://www.ncbi.nlm.nih.gov/pubmed/28008275 http://dx.doi.org/10.2147/OTT.S101385

Ejemplares similares

Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor
por: Asahi, Yoh, et al.
Publicado: (2018)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

2023 GEIS Guidelines for gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2023)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Sunitinib Treatment for Multiple Brain Metastases from Jejunal Gastrointestinal Stromal Tumor: Case Report
por: TAKEUCHI, Hayato, et al.
Publicado: (2014)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Current treatment strategies and future perspectives for gastrointestinal stromal tumors
por: Sugiyama, Yoichi, et al.
Publicado: (2022)

Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib
por: Pallotti, Maria Caterina, et al.
Publicado: (2012)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
por: Brohl, Andrew S., et al.
Publicado: (2015)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
por: Verschuur, Arnauld C., et al.
Publicado: (2019)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report
por: LIU, YAN, et al.
Publicado: (2013)

Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine
por: Ogata, Misato, et al.
Publicado: (2019)

Debulking of Advanced Gastrointestinal Stromal Tumor With Peritoneal Carcinomatosis Refractory to Imatinib and Sunitinib: A Case Report
por: Rave, Talia E., et al.
Publicado: (2021)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters
por: Chang, Yau-Ren, et al.
Publicado: (2021)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Preoperative therapy with sunitinib malate in a patient with a gastrointestinal stromal tumor and liver metastases: A case report
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Gastrointestinal stromal tumor
por: Stamatakos, Michael, et al.
Publicado: (2009)

Gastrointestinal stromal tumors
por: Beham, Alexander W., et al.
Publicado: (2011)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
por: Kong, Seong-Ho, et al.
Publicado: (2013)

Syndromic gastrointestinal stromal tumors
por: Ricci, Riccardo
Publicado: (2016)

Pathology of Gastrointestinal Stromal Tumors
por: Foo, Wai Chin, et al.
Publicado: (2012)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor: A case report
por: Nie, Yanli, et al.
Publicado: (2019)

Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review
por: Xie, Fuming, et al.
Publicado: (2019)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7ddkgukd819ieqnoj42hcu6iuk